The Androgen Receptor in Prostate Cancer: Therapy Target in Search of an Integrated Diagnostic Test
- 1 September 2007
- journal article
- review article
- Published by Wolters Kluwer Health in Advances in Anatomic Pathology
- Vol. 14 (5) , 353-357
Abstract
Despite the near ubiquitous use of therapies targeting the androgen receptor (AR) axis in prostate cancer, there remains, at this date, no integrated diagnostic test designed to select and individualize patients for hormonal-based treatments. From the article by Chmelar and coauthors, we may have a glimpse as to a way forward to the development of a test that can successfully guide the use of androgen ablation therapy. By turning our attention away from the AR gene and protein itself and focusing on coregulators of the AR pathway we may have a new opportunity to develop a single or group of slide-based tests designed to assess AR pathway status on the needle biopsy of a newly diagnosed prostate cancer patient and predict the clinical benefit of total androgen blockade treatment strategies.Keywords
This publication has 15 references indexed in Scilit:
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerJournal of Clinical Oncology, 2007
- Androgen receptor coregulators and their involvement in the development and progression of prostate cancerInternational Journal of Cancer, 2006
- Estrogen Receptor Testing of Breast Cancer in Current Clinical Practice: What's the Question?Journal of Clinical Oncology, 2006
- Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling AxisJournal of Clinical Oncology, 2005
- Targeting the androgen receptor in hormone-refractory prostate cancer ? new conceptsFuture Oncology, 2005
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerNew England Journal of Medicine, 2004
- High Level of Androgen Receptor Is Associated With Aggressive Clinicopathologic Features and Decreased Biochemical Recurrence-free Survival in ProstateAmerican Journal of Surgical Pathology, 2004
- Androgen receptor polymorphisms and risk of biochemical failure among prostatectomy patientsThe Prostate, 2004
- Molecular determinants of resistance to antiandrogen therapyNature Medicine, 2003
- Immunohistochemistry and biochemistry in detection of androgen, progesterone, and estrogen receptors in benign and malignant human prostatic tissueThe Prostate, 1992